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CARDIAC AND PULMONARY 
REPLACEMENT 
DIRECT GENE TRANSFER 
INTO DONOR HEARTS AT 
THE TIME OF HARVEST 
Access to the donor heart at the time of harvest provides a unique opportunity for 
genetic manipulation of this organ before transplantation. We sought o determine (1) 
if donor mouse hearts express a foreign gene administered atharvest and, (2) if so, what 
route of gene delivery is most effective. At harvest, 30/.tg of promoter cytomegalovirus- 
luciferase deoxyribonucleic plasmid in cationic liposomes was injected irectly into the 
myocardial pex (group I), into the right atrium (group Il), or into the coronary arteries 
(group HI). The donor hearts were then transplanted into the abdomen of recipient mice 
of the same strain. The transplanted hearts were removed in 4 days and luciferase 
expression was assayed by immunohistochemistry. In group I, luciferase activity was 
localized to the apex. In group H, where plasmid was delivered into the right 
atrium, luciferase xpression was detected in the right ventricle and sparsely in the 
coronary perivascular ea. In group HI, where plasmid was injected into the coronary 
arteries, the transplanted hearts demonstrated luciferase expression in (1) perivascular 
areas surrounding coronary teries and veins, (2) coronary capillaries, and (3) the 
endocardia of both ventricles. This study suggests that (1) donor mouse hearts can be 
genetically modified at the time of harvest and (2) intracoronary infusion of plasmid 
yields the most effective method of delivery. Administration of plasmid in the coronary 
arteries localizes the expression to the endocardium and the coronary vasculature, both 
sites of immunologic nteractions after heart transplantation. (J THORAC CARDIOVASC 
SURG 1995;109:716-20) 
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T he concept of gene transfer refers to alteration of genetic content of target cells via addition of 
foreign genes. The development of technology to 
transfer genetic material into the heart and vascu- 
lature of experimental nimal models has opened 
new frontiers in studying the pathogenesis and treat- 
ment of cardiovascular diseases. The objective of 
gene therapy is the efficient delivery of desired 
genetic material to target cells, resulting in stable 
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and localized production of a recombinant protein. 
The feasibility of gene transfer to arterial wall cells 
has been demonstrated in several animal models 
with a variety of techniquesJ -s However, an optimal 
system for direct in vivo gene transfer that meets all 
of these criteria is yet to be developed. 
The application of gene transfer to the field of 
transplantation is uniquely appealing because of 
access to the donor organ at the time of harvest. It 
is potentially feasible that a foreign gene may be 
transferred to the harvested organ, creating a 
"transgenic" allograft. The application of gene 
transfer techniques to experimental transplantation 
has been limited. 6 We therefore sought to deter- 
mine (1) if donor mouse hearts express a foreign 
gene administered at harvest and (2) if so, what 
route of gene delivery is most effective. 
Methods 
Construction of expression vector. The firefly lucif- 
erase gene was used as the marker gene for this study. The 
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plasmid expression vector, pCMV-luciferase, consisted of 
a full-length firefly Photinus pyralis luciferase complemen- 
tary deoxyribonucleic a id (cDNA) under the control of 
cytomegalovirus promoter/enhancer. 2 The vehicle for 
transfer was cationic liposome. Thirty micrograms of 
CMV-luciferase DNA plasmid and 50 /xg of cationic 
liposomes (N- [ 1- (2,3-dioleyloxy)propyl]-N,N,N-trimethyl- 
ammonium chloride; Lipofectin; Bethesda Research Lab- 
oratories, Gaithersburg, Md.) were added to reduced 
serum medium (Opti-MEM; Gibco Laboratories, Grand 
Island, N.Y.) to a final volume of 200 /xl. The DNA- 
liposome solution was prepared approximately 30minutes 
before the transfection procedure. 
Experimental groups. Both donor and recipient mice 
were of C57BL/6 strains (Jackson Laboratories, Bar Har- 
bor, Maine). Donor hearts were arrested with cold, dilute 
(because of high viscosity) University of Wisconsin solu- 
tion (Du Pont Pharmaceutical, Wilmington, Del.). In 
group I (n = 4), the DNA-liposome solution was directly 
injected into the myocardial apex on cardiac arrest. The 
plasmid-liposome solution in group II (n = 4) was admin- 
istered through the inferior vena cava into the right 
atrium. In group III (n = 4), with the distal ascending 
aorta clamped, the plasmid-liposome solution was directly 
injected into the ascending aorta over 2 to 3 minutes. 
Transplantation. Heterotopic intraabdominal trans- 
plantation was performed by means of the technique 
previously described by Corey, Winn, and Russell. 7 In 
brief, donor hearts were arrested with dilute, cold Univer- 
sity of Wisconsin solution. The plasmid-liposome solution 
was administered according to the protocol described 
earlier. The donor hearts were excised in standard fashion 
and stored in University of Wisconsin solution until the 
recipient was prepared. During this time, the transfection 
medium was in contact with the donor heart. The plasmid- 
liposome solution was not washed out of the donor organ 
before transplantation. The heterotopic cardiac transplan- 
tation was performed by anastomosing the donor aorta to 
the side of the recipient infrarenal aorta. An end-to-side 
anastomosis between the donor pulmonary artery and 
recipient infrarenal inferior vena cava was performed 
hext. The total ischemic time was 45 minutes to 1 hour, 
which was also the duration of exposure of donor hearts to 
plasmid-liposome solution. The function of the trans- 
planted bearts was assessed aily by abdominal palpation. 
All animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Analysis of lueiferase xpression. The transplanted and 
recipient hearts were harvested in 4 days when the mice 
were sacrificed. Multiple 10/xm thick cross sections of the 
hearts at the apex and midportion of the ventricle were 
obtained. Luciferase xpression was assayed immunohis- 
tochemically with a polyclonal rabbit immunoglobulin G 
(Cortex Biochem, Inc., Sah Leandro, Calif.). Immunohis- 
tochemical staining was performed in a three-step indirect 
avidin-biotin immunoperoxidase assay (Vector, ABC Kit, 
Table I. Luciferase xpression on the donor mouse 
hearts at the mid-ventricular level 
Group I Group H Group III 
Right ventricular endocardium - + + 
Left ventricular endocardium - - + 
Capillaries - -+ + 
Coronary perivascular ea - _+ + 
+, Always present; _% occasionally present; -, abseht. 
Burlingame, Calif.). 8 Luciferase xpression was assessed 
by one of us (J.H.Q.) in a blind fashion. 
Results 
All donor hearts were functioning well at the time 
of harvest; no acute cellular rejection was apparent 
on histologic evaluation. Immunohistochemical 
staining of the donor hearts at the mid-ventricular 
level for luciferase xpression is illustrated in Table 
I. The mid-ventricular c oss sections of the hearts in 
group I did not reveal any luciferase expression. 
However, when apical cross sections were examined, 
luciferase xpression could be detected on the apical 
vasculature and myocytes. In group II, the plasmid- 
liposome solution was administered through the 
inferior vena cava into the right atrium; the donor 
hearts in this group revealed luciferase expression 
on the right ventricular endocardium and sparse 
expression around the coronary vasculature. No 
luciferase expression could be detected on the left 
ventricular endocardium in group II. In group III, 
plasmid-liposome solution was injected into the 
aortic root, perfusing the coronary arteries in an 
antegrade fashion. Luciferase expression was evi- 
dent on the left ventricular endocardium, right 
ventricular endocardium, coronary capillaries, and 
around the coronary vessels (Figs. 1 and 2). 
Although double immunostaining to identify the 
transfected cell types was not carried out, luciferase 
expression appeared to be present on endothelial 
cells, some arterial smooth muscle cells, and some 
myocytes on review of adjacent sections. The recip- 
ient mouse hearts of all groups underwent identical 
immunohistochemical processing and no luciferase 
expression could be identified. 
Diseussion 
The findings of this study suggest that donor 
mouse hearts can be transfected at the time of 
harvest. Intracoronary infusion of plasmid appeared 
to be an efficacious route of delivery of reporter 
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Fig. 1. Mid-ventricular cross section of a donor heart in group III immunostained for luciferase 
expression. In this group, the plasmid-liposome solution was injected into the aortic root. Luciferase 
expression was detectable on both ventricular endocardia. 
Fig. 2. Luciferase xpression on a mid-ventricular c oss section of a donor heart in group III. Luciferase 
activity was detected around coronary vasculature. 
plasmid, yielding detectable xpression on the en- 
docardia, coronary capillaries, and perivascular 
area. Expression of the reporter plasmid was local- 
ized to the transplanted hearts and did not appear to 
induce cellular rejection of the isografts. 
The utility and importance of gene therapy for 
several disorders has recently been reviewed. 9'10 
Direct in vivo gene transfer to vascular wall cells 
represents an ideal system for production of se- 
creted proteins with locally therapeutic effects. Ex- 
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tension of the principles of experimental gene trans- 
fer to heart transplantation has been limited. Wang 
and associates 6 studied the expression of reporter 
genes in a rat cardiac isograft model after direct 
apical gene injection. They observed stable expres- 
sion of the reporter gene locally for 2 months. The 
present study demonstrates that foreign genes can 
be introduced into the donor hearts at the time of 
harvest. Among the three tested routes of delivery, 
the intracoronary administration of expression vec- 
tor yielded the most widespread and strategically 
important ransfection. Luciferase expression was 
observed on the endothelial cells and in the perivas- 
cular area. The endocardium and perivascular area, 
the sites of initial host-recipient immunologic inter- 
action, are the ideal sites for introduction of genes 
intended to alter the immune response. This study 
further documents that gene transfer to the donor 
hearts at the time of harvest is safe (no evidence of 
cellular rejection in transplanted hearts), localized 
(reporter plasmid expression confined to the donor 
heart), and feasible. 
Application of direct gene transfer techniques to 
the field of heart transplantation ffers several pos- 
sibilities: (1) studying the role of individual genes 
separately in immunologic interactions, (2) the de- 
velopment of localized therapeutic measures limited 
to the donor heart, (3) evaluation of gene regulato- 
ry/promoter mechanisms responsible for expression 
of endogenous proteins such as histocompatibility 
antigens, and (4) alteration of donor organ "foreign- 
ness" by controlling human leukocyte antigen 
(HLA) expression via antisense oligonucleotide 
transfer. 1~ The latter technique allows for transfer of 
recombinant genes coding for messenger ribonu- 
cleic acid (mRNA), which binds to HLA mRNA and 
effectively blocks HLA expression. Genetic modifi- 
cation of nonhuman hearts to allow xenotransplan- 
tation is an established area of investigationJ 2 Ap- 
plication of gene transfer technology at the time of 
donor procurement to the field of xenotransplanta- 
tion may further the goals of this area of research. 
Improvements in gene transfer methods to yield 
efficient delivery techniques, producing biologically 
effective recombinant protein levels, in specific cel- 
lular targets are needed to further the applications 
of gene therapy in transplantation. 
In conclusion, donor mouse hearts can be trans- 
fected by a reporter plasmid at the time of harvest. 
Intracoronary infusion of reporter plasmid yielded 
detectable xpression in perivascular areas and en- 
docardia, both sites of immunologic interaction be- 
tween the donor and the host after transplantation. 
Intracoronary administration of plasmid may allow 
genetic alteration of donor organs in the near 
future. 
We gratefully acknowledge the technical assistance of 
Thomas Drake, MD, in photomicrography. 
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Diseussion 
Dr. Robert A. Guyton (Atlanta, Ga.). I am eonfused 
about he exposure of the plasmid to the donor heart. Was 
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the plasmid-luciferase combination injected before arrest 
of the donor heart, that is, while the donor heart was 
metabolically active, and what was the duration of expo- 
sure of the donor heart to the plasmid? Was the donor 
heart at 4 ° C while the plasmid was exposed to the donor 
heart? 
Dr. Ardehali. The donor hearts were arrested with 
University of Wisconsin solution; the plasmid-liposome 
solution was then administered according to the described 
protocol. The allografls were not flushed thereafter. The 
hearts were then preserved in cold University of Wiscon- 
sin solution for 45 minutes to 1 hour until the recipients 
were prepared. Therefore, transfection occurred during 
the cold ischemic time (45 minutes to 1 hour). 
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